Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
166 hedge funds and large institutions have $2.29B invested in Soleno Therapeutics in 2024 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 78 increasing their positions, 25 reducing their positions, and 24 closing their positions.
212% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 25
104% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 24
17% more funds holding
Funds holding: 142 → 166 (+24)
2% less call options, than puts
Call options by funds: $120M | Put options by funds: $123M
4% less capital invested
Capital invested by funds: $2.38B → $2.29B (-$85M)
2.86% less ownership
Funds ownership: 121.22% → 118.37% (-2.9%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$57.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$49.3M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$34.1M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20M |
| 5 |
Holocene Advisors
New York
|
+$18.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$140M |
| 2 |
PA
Perceptive Advisors
New York
|
-$88.3M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$28.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$16.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCP
176
Corbin Capital Partners
New York
| – | -$590K | -11,685 | Closed |
|
|
EGM
177
Engineers Gate Manager
New York
| – | -$563K | -11,157 | Closed |
|
|
VU
178
Valence8 US
Cambridge,
Massachusetts
| – | -$490K | -9,706 | Closed |
|
|
VF
179
Virtu Financial
New York
| – | -$490K | -9,706 | Closed |
|
|
DM
180
Deerfield Management
New York
| – | -$342K | -6,774 | Closed |
|
181
Dimensional Fund Advisors
Austin,
Texas
| – | -$228K | -4,522 | Closed |
|
|
NRD
182
Nebula Research & Development
New York
| – | -$220K | -4,358 | Closed |
|
|
CRC
183
Curi RMB Capital
Chicago,
Illinois
| – | -$202K | -4,000 | Closed |
|
184
Acadian Asset Management
Boston,
Massachusetts
| – | -$76K | -1,523 | Closed |
|
|
CPA
185
Capital Performance Advisors
Walnut Creek,
California
| – | -$858 | -17 | Closed |
|
186
Russell Investments Group
London,
United Kingdom
| – | -$555 | -11 | Closed |
|
|
SAM
187
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$442 | -9 | Closed |
|
188
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$50 | -1 | Closed |
|
SLNO Hedge Fund Activity: Q4 2024 in Review
166 of the 7,602 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2024, worth a combined $2.29B — down 3.6% from $2.38B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new SLNO positions and 24 closed out — a net gain of 25 holders — while 78 added to existing stakes and 25 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $57.4M. The largest seller was Carlyle Group, cutting an estimated $140M.
- 166 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2024, up from 142 in Q3 2024.
- Funds reported $2.29B of Soleno Therapeutics stock for Q4 2024, down 3.6% quarter-over-quarter.
- 49 funds opened new Soleno Therapeutics positions in Q4 2024 and 24 closed out, a net change of +25 holders.
- The largest Soleno Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $57.4M added.
- The largest Soleno Therapeutics seller in Q4 2024 was Carlyle Group, an estimated $140M sold.
Based on aggregated 13F filings for Q4 2024.